European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma | Small Molecules

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

Related Keywords

France ,Germany ,Norway ,Iceland ,Stockholm ,Sweden ,United Kingdom ,Italy ,Liechtenstein ,Spain ,Lichtenstein ,Oncopeptides Pepaxti ,Rolf Gulliksen ,Jakob Lindberg ,Oncopeptide Pepaxti ,European Commission ,Global Head Of Corporate Communications ,Swedeni August ,Nasdaq Stockholm ,European Economic Area ,Global Head ,Corporate Communications ,Multiple Myeloma ,Mid Cap ,Small Molecule ,New Chemical Entity ,Ice ,Chemistry ,Mural ,Inhaled ,Drug Delivery ,Depot ,Flow Release ,